SSY Group Wins China Approval for New Irrigation and Bumetanide Injectables

SSY Group ( (HK:2005) ) just unveiled an update.

SSY Group has received Chinese regulatory approvals for production and registration of its Sodium Lactate Ringer’s Irrigation Solution (3000ml) and Bumetanide Injection (2ml:1mg), both classified as type 3 chemical drugs that have passed consistency evaluation. The irrigation solution is the first of its kind approved for PRC entities for general rinsing with sterile electrolyte solutions, while the Bumetanide Injection addresses edema linked to heart, renal and hepatic conditions as well as several electrolyte and blood pressure disorders, marking a further step after the group’s earlier approval for its Bumetanide bulk drug and underscoring its expanding injectable portfolio in China’s hospital drug market.

The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a pharmaceutical company focused on the development and production of chemical drug formulations for the China market. The group specialises in injectable and irrigation solutions for clinical use, targeting hospital and institutional demand across a range of therapeutic areas including cardiovascular, renal and critical care.

Average Trading Volume: 8,256,822

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.05B

See more insights into 2005 stock on TipRanks’ Stock Analysis page.